- Investing.com
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
तुलना करने के लिए मीट्रिक्स | 302440 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध302440पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −88.4x | −10.6x | −0.6x | |
PEG अनुपात | 0.45 | 0.03 | 0.00 | |
क़ीमत/बुक | 2.2x | 2.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 19.0x | 13.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | −0.7% | 43.1% | 48.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.2% | 7.7% | अनलॉक करें |